Arcellx Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Raises Target Price to $121
Arcellx Initiated With a Buy at Redburn Atlantic
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $85
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $85
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $85
Arcellx Inc's Anito-cel Shows Promising Efficacy in Treating Challenging Multiple Myeloma, Merits Buy Rating
Arcellx Analyst Ratings
Cantor Fitzgerald Initiates Arcellx(ACLX.US) With Buy Rating
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $85
Buy Rating for Arcellx Inc: Operational Efficiencies and Market Advantages Over Legend/JnJ Propel Positive Outlook
Buy Rating Affirmed for Arcellx Inc. on Strong CAR-T Therapy Prospects and Financial Stability
Analysts Are Bullish on These Healthcare Stocks: Royalty Pharma (RPRX), Arcellx Inc (ACLX)
Piper Sandler Issues a Buy Rating on Arcellx Inc (ACLX)
Arcellx Analyst Ratings
Buy Rating Affirmed: Arcellx Inc's Growth Potential Bolstered by FDA Clearance, Strategic Partnerships, and Strong Financial Outlook
Arcellx Inc: Buy Rating Affirmed Amid Promising Clinical Trials and Market Potential
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $85
Buy Rating Justified: Arcellx Inc's Promising CART DdBCMA Treatment and Competitive Edge Analyzed by John Newman
Arcellx Price Target Maintained With a $85.00/Share by Canaccord Genuity